
    
      Patients are randomized to receive one of two drug regimens: BMS-232632, ddI, and d4T or NFV,
      ddI, and d4T. Three different doses of BMS-232632 are used in this study. Randomization is
      stratified for HIV RNA level (less than 30,000 copies/ml versus 30,000 or greater copies/ml).
      Patients remain on their drug regimen for 48 weeks.
    
  